KBC Group NV Cuts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

KBC Group NV decreased its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 40.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 82,346 shares of the company's stock after selling 56,297 shares during the period. KBC Group NV's holdings in Moderna were worth $5,503,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Ashton Thomas Private Wealth LLC purchased a new position in Moderna in the second quarter valued at approximately $26,000. Family Firm Inc. bought a new position in shares of Moderna during the 2nd quarter worth $33,000. Bank & Trust Co bought a new stake in Moderna in the 2nd quarter valued at about $36,000. Hanseatic Management Services Inc. purchased a new position in shares of Moderna in the second quarter worth about $48,000. Finally, Plato Investment Management Ltd lifted its stake in shares of Moderna by 230.4% during the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company's stock valued at $49,000 after buying an additional 288 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

MRNA has been the topic of a number of research reports. Needham & Company LLC reissued a "hold" rating on shares of Moderna in a report on Friday, November 8th. Deutsche Bank Aktiengesellschaft upgraded Moderna from a "sell" rating to a "hold" rating and dropped their target price for the company from $85.00 to $80.00 in a report on Wednesday, August 7th. UBS Group reduced their target price on Moderna from $140.00 to $108.00 and set a "buy" rating on the stock in a research note on Thursday, October 24th. JPMorgan Chase & Co. cut their price target on shares of Moderna from $70.00 to $59.00 and set an "underweight" rating on the stock in a report on Monday, November 4th. Finally, Barclays cut their target price on shares of Moderna from $125.00 to $111.00 and set an "overweight" rating on the stock in a research note on Friday, November 8th. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $86.33.

Insiders Place Their Bets

In other news, CFO James M. Mock sold 715 shares of the business's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares of the company's stock, valued at $571,440.60. The trade was a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders sold 2,930 shares of company stock valued at $217,170. 15.70% of the stock is currently owned by corporate insiders.

Moderna Trading Up 6.9 %

Shares of Moderna stock traded up $2.55 during trading on Monday, hitting $39.40. The stock had a trading volume of 11,294,563 shares, compared to its average volume of 4,739,954. The stock has a market cap of $15.16 billion, a PE ratio of -6.70 and a beta of 1.69. The firm's fifty day simple moving average is $58.56 and its 200-day simple moving average is $96.68. Moderna, Inc. has a 12 month low of $35.80 and a 12 month high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating analysts' consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. Moderna's revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the company posted ($1.39) EPS. As a group, sell-side analysts expect that Moderna, Inc. will post -9.43 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.